GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -5.6% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 6 | +1 | 5.67M | $830.55M | +1 | n/a |
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | n/a |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | n/a | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | n/a | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | n/a | n/a |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | n/a |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | n/a | n/a |
| Q2 2024 | 18 | n/a | 202.41M | $13.88B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 59.52M | -1.4% | $6.67B | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 2 | Capital World Investors ✦ | 53.55M | -25.3% | $6.00B | 1.0% | ▼ Trim | 4 | SEC ↗ |
| 3 | Dodge & Cox ✦ | 32.69M | -0.8% | $3.66B | 2.1% | ▼ Trim | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 28.48M | +0.7% | $3.19B | 0.3% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Wellington Management ✦ | 27.36M | -23.3% | $3.07B | 0.6% | ▼ Trim | 4 | SEC ↗ ×9 |
| 6 | Norges Bank ✦ (passive) | 19.86M | +2.5% | $2.22B | 0.3% | ▲ Add | 4 | SEC ↗ |
| 7 | T. Rowe Price ✦ | 14.70M | +314.6% | $1.65B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 8 | Renaissance Technologies ✦ | 5.45M | +2.3% | $610.80M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 5.37M | +14.4% | $602.15M | 0.6% | ▲ Add | 4 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 2.54M | +271.9% | $284.44M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.86M | +2.8% | $207.37M | 0.2% | ▲ Add | 4 | SEC ↗ ×6 |
| 12 | Adage Capital Partners ✦ | 1.32M | -23.0% | $147.92M | 0.3% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 773.87K | -36.4% | $86.71M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | Point72 Asset Management ✦ | 510.74K | -40.4% | $57.23M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 15 | Bridgewater Associates ✦ | 502.95K | +9.1% | $56.36M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 453.76K | -55.2% | $50.84M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 17 | Gotham Asset Management ✦ | 250.99K | -2.0% | $28.12M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 18 | Arrowstreet Capital ✦ | 53.99K | -61.3% | $6.05M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 43.40K | -81.9% | $4.86M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 6.95K | -34.5% | $778,788 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 61.30K shares, $8,543 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.00K sh · $468,660
Officer · 3.00K sh · $468,660
Officer · 600 sh · $87,174
Officer · 800 sh · $115,566
Officer · 1.60K sh · $229,907
Officer · 3.00K sh · $435,870
Officer, Director · 1.60K sh · $236,014
Officer, Director · 7.99K sh · $1.19M
Officer, Director · 5.41K sh · $807,856
Director · 6.88K sh · $1.02M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology